The Menopause Charity
Veoza (Fezolinetant) - A new non-hormonal treatment for menopausal symptoms
Veoza (Fezolinetant) is a new non-hormonal treatment providing relief specifically for hot flushes and night sweats. This article delves into the key aspects of Veoza, its recommended usage, licensing status, and the evolving landscape of menopause management.
Who is this treatment suitable for?
Unlike traditional hormone replacement therapies (HRT) that rely on oestrogen and progesterone, Veoza works on the brain’s temperature-control centre to alleviate hot flushes and night sweats.
Veoza is primarily recommended for women who cannot take hormone replacement therapy. This includes individuals with a history of specific cancers or active blood clots. Notably, the treatment is not licensed for women with a history of breast cancer, underlining the importance of personalised healthcare decisions based on individual medical histories.
Availability and Approval
Veoza is now set to be released in the private sector. The estimated cost of Veoza in the private sector is £44.80 per month, alongside a specialist consultation fee. This treatment has not yet received approval for use within the NHS. A NICE review is underway to consider the clinical and cost-effectiveness of the treatment.
Limitations and Scope
It is important for potential users to recognise the specific focus of Veoza on alleviating hot flushes and night sweats. This treatment does not address other common menopausal symptoms such as brain fog, tiredness, or joint pains.
Hormone replacement therapy remains the most widely accepted and cost-effective first-line treatment for menopause, for those who can take it. However, for a small group who may otherwise have few options, may find Veoza of benefit to manage their vasomotor symptoms.
As Veoza enters the private sector and undergoes ongoing trials for NHS approval, it introduces an alternative for managing menopausal symptoms for a very small group of patients. Its role in the broader landscape of menopause management will become clearer as more data emerges, offering healthcare professionals and patients alike a valuable tool in tailoring treatment approaches to individual needs.